The latest health news includes WuXi's sale of its Advanced Therapies unit due to US restrictions, expanding famine in Sudan ...

California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Leveraging insights from OpenAI’s ChatGPT, Finbold has curated a $1,000 stock portfolio designed to capture growth ...

We recently compiled a list of the Tech Billionaire Chase Coleman’s Top 10 Stock Picks. In this article, we are going to take ...

Eli Lilly (LLY) closed at $795.67 in the latest trading session, marking a -0.08% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.1%. Elsewhere, the Dow ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 502.93% and ...

The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...

Differences in how men and women manifest and experience psoriatic arthritis suggest it’s time to think of patient sex as a ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...